Understanding and blocking HIV reverse transcriptase
Mechanism and Inhibition of HIV Reverse Transcriptase
This study is exploring how a crucial enzyme in HIV works to create new medications that can better fight HIV, including strains that are resistant to current treatments, so that people living with HIV can have safer and more effective options for their care.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11117078 on NIH RePORTER |
What this research studies
This research investigates the mechanisms of HIV reverse transcriptase, a key enzyme in the HIV lifecycle, and aims to develop new inhibitors to combat HIV infection. By utilizing advanced computational methods and structure-guided design, the team is working on creating novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are effective against both wild-type and drug-resistant strains of HIV. The goal is to enhance the safety and efficacy of antiretroviral therapies, ultimately improving patient compliance and treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV, particularly those experiencing drug resistance or side effects from current therapies.
Not a fit: Patients who are not infected with HIV or those who have already achieved viral suppression with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for HIV, potentially improving the quality of life for millions of patients.
How similar studies have performed: Previous research has shown success in developing new antiretroviral therapies targeting HIV reverse transcriptase, indicating a promising avenue for further exploration.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Anderson, Karen S. — Yale University
- Study coordinator: Anderson, Karen S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.